Ultragenyx Pharmaceutical, Inc. (RARE)
23.00
+0.22
(+0.97%)
USD |
NASDAQ |
Dec 31, 16:00
22.93
-0.07
(-0.30%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Cash from Investing (Quarterly): 117.18M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Regeneron Pharmaceuticals, Inc. | -402.90M |
| Amicus Therapeutics, Inc. | -1.299M |
| Geron Corp. | 13.35M |
| Vertex Pharmaceuticals, Inc. | -117.00M |
| Fortress Biotech, Inc. | 2.87M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -91.42M |
| Cash from Financing (Quarterly) | 0.002M |
| Free Cash Flow | -466.39M |
| Free Cash Flow Per Share (Quarterly) | -0.9291 |
| Free Cash Flow to Equity (Quarterly) | -72.91M |
| Free Cash Flow to Firm (Quarterly) | -78.48M |
| Free Cash Flow Yield | -20.79% |